Home
ADAP
ADAP News

Latest Adaptimmune Therapeutics plc (ADAP) News on July 4, 2024

5 FDA decisions to watch in the third quarter

BioPharma Dive

a day ago

5 FDA decisions to watch in the third quarter

Zacks Small Cap Research

2 days ago

Fireside Chat with Adrian Rawcliffe, Chief Executive Officer of Adaptimmune

ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company

Zacks Small Cap Research

22 days ago

ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

Yahoo Finance Video

24 days ago

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

GlobeNewswire

24 days ago

Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis

California seeks company profits in Big Oil climate lawsuit

Reuters

24 days ago

California seeks company profits in Big Oil climate lawsuit

USA TODAY

24 days ago

S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

GlobeNewswire

24 days ago

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Business Wire

24 days ago

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

Business Wire

24 days ago

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

GlobeNewswire

24 days ago

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

Lotto 6/49 - $64 million up for grabs in the next draw!

CNW Group

25 days ago

Lotto 6/49 - $64 million up for grabs in the next draw!

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Simply Wall St.

25 days ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North

AFP

25 days ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

Simply Wall St.

25 days ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Simply Wall St.

25 days ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Barrons.com

25 days ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

Simply Wall St.

25 days ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Simply Wall St.

25 days ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise

Newsfile

a month ago

Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise

MT Newswires

a month ago

Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

Newsfile

a month ago

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

MT Newswires

a month ago

Scotiabank Starts Adaptimmune Therapeutics With Sector Outperform Rating

MT Newswires

2 months ago

Mizuho Slashes Price Target on Adaptimmune Therapeutics to $3 From $9, Keeps Buy Rating

MT Newswires

2 months ago

Adaptimmune Therapeutics Enters Into $125 Million Term Loan Facility With Hercules Capital

Adaptimmune Reports Q1 2024 Financial and Business Updates

Newsfile

2 months ago

Adaptimmune Reports Q1 2024 Financial and Business Updates

Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital

Newsfile

2 months ago

Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital

Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024

Newsfile

2 months ago

Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024

Adaptimmune (ADAP) Down on End of Collaboration With Roche

Zacks

3 months ago

Adaptimmune (ADAP) Down on End of Collaboration With Roche

Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated

Newsfile

3 months ago

Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated

Roche, Adaptimmune part ways on cell therapy research

BioPharma Dive

3 months ago

Roche, Adaptimmune part ways on cell therapy research

Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet

Newsfile

3 months ago

Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet

Adaptimmune Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

4 months ago

Adaptimmune Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results

GuruFocus.com

4 months ago

Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript

Insider Monkey

4 months ago

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript

Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates

Newsfile

4 months ago

Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

Newsfile

4 months ago

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024

Newsfile

4 months ago

Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024

15 Top Performing European Stocks So Far in 2024

Insider Monkey

5 months ago

15 Top Performing European Stocks So Far in 2024

Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know

Zacks

5 months ago

Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

Newsfile

5 months ago

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

Baillie Gifford Increases Stake in Adaptimmune Therapeutics PLC

GuruFocus.com

5 months ago

Baillie Gifford Increases Stake in Adaptimmune Therapeutics PLC

With 30% stake, 1stdibs.Com, Inc. (NASDAQ:DIBS) seems to have captured institutional investors' interest

Simply Wall St.

5 months ago

With 30% stake, 1stdibs.Com, Inc. (NASDAQ:DIBS) seems to have captured institutional investors' interest

First Mid Bancshares Full Year 2023 Earnings: EPS Misses Expectations

Simply Wall St.

5 months ago

First Mid Bancshares Full Year 2023 Earnings: EPS Misses Expectations

RBB Bancorp (NASDAQ:RBB) Q4 2023 Earnings Call Transcript

Insider Monkey

5 months ago

RBB Bancorp (NASDAQ:RBB) Q4 2023 Earnings Call Transcript

Alimera Sciences (NASDAQ:ALIM) shareholders have endured a 69% loss from investing in the stock five years ago

Simply Wall St.

5 months ago

Alimera Sciences (NASDAQ:ALIM) shareholders have endured a 69% loss from investing in the stock five years ago

Why WW International Stock Bounced 6% Higher Today

Motley Fool

5 months ago

Why WW International Stock Bounced 6% Higher Today

Cohen & Steers Announces Retirement of William Scapell, Head of Fixed Income and Preferred Securities, Effective August 1, 2024

PR Newswire

6 months ago

Cohen & Steers Announces Retirement of William Scapell, Head of Fixed Income and Preferred Securities, Effective August 1, 2024

Dakota Gold Intersects Multiple High-Grade Zones with Visible Gold Mineralization, Including 4.871 oz/ton Au over 3.4 ft (167.0 g/t over 1.0 m), 1200 feet South of the JB Gold Zone on Its Maitland Gold Project

Newsfile

6 months ago

Dakota Gold Intersects Multiple High-Grade Zones with Visible Gold Mineralization, Including 4.871 oz/ton Au over 3.4 ft (167.0 g/t over 1.0 m), 1200 feet South of the JB Gold Zone on Its Maitland Gold Project

Adaptimmune Therapeutics (NASDAQ:ADAP shareholders incur further losses as stock declines 22% this week, taking three-year losses to 88%

Simply Wall St.

6 months ago

Adaptimmune Therapeutics (NASDAQ:ADAP shareholders incur further losses as stock declines 22% this week, taking three-year losses to 88%

Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why

Zacks

6 months ago

Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why

Insider Sell: Solid Power Inc CTO Joshua Buettner-garrett Sells 187,500 Shares

GuruFocus.com

6 months ago

Insider Sell: Solid Power Inc CTO Joshua Buettner-garrett Sells 187,500 Shares

Smartfren Telecom and Aviat Establish Strategic Collaboration in Indonesia

PR Newswire

6 months ago

Smartfren Telecom and Aviat Establish Strategic Collaboration in Indonesia

Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference

PR Newswire

6 months ago

Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference

The Zacks Analyst Blog Highlights VirTra, REX American Resources, Universal Stainless & Alloy Products, Runway Growth Finance and Carrols Restaurant Group

Zacks

6 months ago

The Zacks Analyst Blog Highlights VirTra, REX American Resources, Universal Stainless & Alloy Products, Runway Growth Finance and Carrols Restaurant Group

Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference

Newsfile

6 months ago

Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference

Camden National Corporation to Announce Quarter and Year Ended December 31, 2023 Financial Results on January 30, 2024

PR Newswire

6 months ago

Camden National Corporation to Announce Quarter and Year Ended December 31, 2023 Financial Results on January 30, 2024

Red River Bancshares (NASDAQ:RRBI) Ticks All The Boxes When It Comes To Earnings Growth

Simply Wall St.

6 months ago

Red River Bancshares (NASDAQ:RRBI) Ticks All The Boxes When It Comes To Earnings Growth

Here's Why We Think Tootsie Roll Industries (NYSE:TR) Might Deserve Your Attention Today

Simply Wall St.

6 months ago

Here's Why We Think Tootsie Roll Industries (NYSE:TR) Might Deserve Your Attention Today

NaaS Technology Inc. Announces Amendment of Share Incentive Plan

PR Newswire

6 months ago

NaaS Technology Inc. Announces Amendment of Share Incentive Plan

Will Gambling.com (GAMB) be a Strong Long-Term Compounder?

Insider Monkey

6 months ago

Will Gambling.com (GAMB) be a Strong Long-Term Compounder?

Calamos Investments Closed-End Funds (NASDAQ: CHI, CHY, CSQ, CGO, CHW, CCD and CPZ) Announce Monthly Distributions and Required Notifications of Sources of Distribution

PR Newswire

7 months ago

Calamos Investments Closed-End Funds (NASDAQ: CHI, CHY, CSQ, CGO, CHW, CCD and CPZ) Announce Monthly Distributions and Required Notifications of Sources of Distribution

Investors Don't See Light At End Of American Well Corporation's (NYSE:AMWL) Tunnel

Simply Wall St.

7 months ago

Investors Don't See Light At End Of American Well Corporation's (NYSE:AMWL) Tunnel

Positive week for Adaptimmune Therapeutics plc (NASDAQ:ADAP) institutional investors who lost 68% over the past year

Simply Wall St.

7 months ago

Positive week for Adaptimmune Therapeutics plc (NASDAQ:ADAP) institutional investors who lost 68% over the past year

Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma

Newsfile

7 months ago

Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma

Exelixis (EXEL) Collaborates With Arcus for Kidney Cancer Study

Zacks

7 months ago

Exelixis (EXEL) Collaborates With Arcus for Kidney Cancer Study

Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND

Zacks

7 months ago

Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND

3 Infrastructure Stocks to Buy as They Build the Future

InvestorPlace

7 months ago

3 Infrastructure Stocks to Buy as They Build the Future

Tech’s Best Kept Secrets: 7 Under-the-Radar Stocks to Watch

InvestorPlace

7 months ago

Tech’s Best Kept Secrets: 7 Under-the-Radar Stocks to Watch

Associated Press Finance

7 months ago

Yirendai: Q3 Earnings Snapshot

PR Newswire

7 months ago

Yiren Digital Reports Third Quarter 2023 Financial Results

Youdao, Inc. (NYSE:DAO) Q3 2023 Earnings Call Transcript

Insider Monkey

8 months ago

Youdao, Inc. (NYSE:DAO) Q3 2023 Earnings Call Transcript

PR Newswire

8 months ago

Yiren Digital to Report Third Quarter 2023 Financial Results on November 21, 2023

Yiren Digital (NYSE:YRD) investors are sitting on a loss of 86% if they invested five years ago

Simply Wall St.

8 months ago

Yiren Digital (NYSE:YRD) investors are sitting on a loss of 86% if they invested five years ago

Thomson Reuters StreetEvents

8 months ago

Q3 2023 Priority Technology Holdings Inc Earnings Call

Priority Technology Holdings Inc (PRTH) Reports Robust Revenue and EBITDA Growth in Q3 2023

GuruFocus.com

8 months ago

Priority Technology Holdings Inc (PRTH) Reports Robust Revenue and EBITDA Growth in Q3 2023

Thomson Reuters StreetEvents

8 months ago

Q3 2023 Kimbell Royalty Partners LP Earnings Call

GuruFocus.com

8 months ago

Kimbell Royalty Partners LP (KRP) Announces Record Q3 2023 Results with Net Income of $18.5 Million

Kimbell Royalty Partners Announces Record Third Quarter 2023 Results

PR Newswire

8 months ago

Kimbell Royalty Partners Announces Record Third Quarter 2023 Results

Associated Press Finance

8 months ago

Faro Technologies: Q3 Earnings Snapshot

FARO Announces Third Quarter Financial Results

PR Newswire

8 months ago

FARO Announces Third Quarter Financial Results

Companhia Brasileira de Distribuição (NYSE:CBD) Q3 2023 Earnings Call Transcript

Insider Monkey

8 months ago

Companhia Brasileira de Distribuição (NYSE:CBD) Q3 2023 Earnings Call Transcript

Share on Social Networks: